These outcomes, in conjunction with IFNγ-activated JAK/STAT1 signaling, promoted the trans-differentiation of tumor-associated macrophages from the M2 to M1 type, remodeled the suppressive tumor immune microenvironment created by iRFA, and restored therapeutic sensitivity to ICIs. The gene discussed is IFNG; the disease is neoplasm.